SCHEMBL8898652

SCHEMBL8898652

CCC(=O)CCCCCCCCCC(C)C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.46
KDM4A O75164 1/20 0.46
PHF8 Q9UPP1 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
FFAR1 O14842 1/20 0.39
CA1 P00915 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
BLM P54132 1/20 0.38
DEGS1 O15121 1/20 0.37
GSTK1 Q9Y2Q3 1/20 0.36
MEN1 O00255 1/20 0.36
FAAH O00519 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL636272 1.00 KDM4C (0.46) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL4054427 1.00 KDM4C (0.46) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL13267741 1.00 KDM4C (0.46) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL13267739 1.00 KDM4C (0.46) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL13509014 0.98 KDM4C (0.43) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL128911 0.91 TDP1 (0.43) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL8039193 0.88 KDM4C (0.50) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL31300438 0.88 KDM4C (0.50) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL28393903 0.88 KDM4C (0.50) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL28399899 0.88 KDM4C (0.50) KDM4CKDM4APHF8KDM2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9644195-B2 Compounds and methods for purification of serine proteases PORTOLA PHARMACEUTICALS, INC. (US) 2017-05-09 US disclosed
US-9200268-B2 Compounds and methods for purification of serine proteases PORTOLA PHARMACEUTICALS, INC. (US) 2015-12-01 US disclosed
US-20150337285-A1 COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) 2015-11-26 US disclosed
US-20140346397-A1 COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) 2014-11-27 US disclosed
US-20140186923-A1 COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES PORTOLA PHARMACEUTICALS, INC. (US) 2014-07-03 US disclosed
US-20100184649-A1 NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS CUBIST PHARMACEUTICALS, INC. 2010-07-22 US disclosed
EP-0531715-B1 Process for producing alcohols and ketones SUMITOMO CHEMICAL CO (JP) 1997-11-05 EP disclosed
US-5426237-A Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde SUMITOMO CHEMICAL CO., LTD. (JP) 1995-06-20 US disclosed
EP-0531715-A1 Process for producing alcohols and ketones SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150337285-A1 COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES PRSS1, HPN, PRSS8 KDM4C 2833/4885KDM4A 3256/4885PHF8 3329/4885
US-20100184649-A1 NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS CLPP, CLPTM1, RPN1 KDM4C 4172/4885KDM4A 4236/4885PHF8 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.